The DOI matches its Crossref record.
Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction
Open accessAbstract
The corneal endothelium maintains corneal transparency; consequently, its dysfunction causes severe vision loss. Tissue engineering-based therapy, as an alternative to conventional donor corneal transplantation, is anticipated to provide a less invasive and more effective therapeutic modality. We conducted a preclinical study for cell-based therapy in a primate model and demonstrated regeneration of the corneal endothelium following injection of cultured monkey corneal endothelial cells (MCECs) or human CECs (HCECs), in combination with a Rho kinase (ROCK) inhibitor, Y-27632, into the anterior chamber. We also evaluated the safety and efficacy of Good Manufacturing Practice (GMP)-grade HCECs, similar to those planned for use as transplant material for human patients in a clinical trial and we showed that the corneal endothelium was regenerated without adverse effect. We also showed that CEC engraftment is impaired by limited substrate adhesion, which is due to actomyosin contraction induced by dissociation-induced activation of ROCK/MLC signaling. Inclusion of a ROCK inhibitor improves efficiency of engraftment of CECs and enables cell-based therapy for treating corneal endothelial dysfunction as a clinically relevant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy
Kinoshita, S., Koizumi, N., Ueno, M., Okumura, N., Imai, K., Tanaka, H., Yamamoto, Y., Nakamura, T., Inatomi, T., Bush, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712770 · Cited by 542
Self-citationHos, D., Matthaei, M., Bock, F., Maruyama, K., Notara, M., Clahsen, T., Hou, Y., Le, V. N. H., Salabarria, A.-C., Horstmann, J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.001 · Cited by 303
Fuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis
Ong Tone, S., Kocaba, V., Böhm, M., Wylegala, A., White, T. L., & Jurkunas, U. V. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100863 · Cited by 284
Hongo, A., Okumura, N., Nakahara, M., Kay, E. P., & Koizumi, N. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-21170 · Cited by 53
Self-citationEffect of a p38 Mitogen-Activated Protein Kinase Inhibitor on Corneal Endothelial Cell Proliferation
Nakahara, M., Okumura, N., Nakano, S., & Koizumi, N. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24394 · Cited by 30
Self-citation
Metadata
- Authors
- Okumura, N., Sakamoto, Y., Fujii, K., Kitano, J., Nakano, S., Tsujimoto, Y., Nakamura, S.-I., Ueno, M., Hagiya, M., Hamuro, J., Matsuyama, A., Suzuki, S., Shiina, T., Kinoshita, S., & Koizumi, N.
- Venue
- Scientific Reports
- Published
- 2016-05-18
- Volume
- 6
- Issue
- 1
- Pages
- 26113-26113
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2405135753
- Cited by
- 183
- References
- 0
- FWCI
- 16.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.